GlassScriptPhysician profile
Praveen Ranganath
NPI 1265745145
$1,713.68
in general payments reported to CMS, 2019-2025
31 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $11.58 · 2023: $147 · 2024: $286 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $294.38 | 2019-2025 | Rybrevant, Akeega, Erleada |
| Merck Sharp & Dohme LLC | $150.24 | 2019-2020 | |
| Ancora Heart, INC. | $149.56 | 2024 | Accucinch |
| Genentech USA, INC. | $135.39 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Amgen INC. | $112.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.44 | 2019-2024 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $80.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.02 | 2019 | |
| Celgene Corporation | $51.93 | 2019-2023 | Reblozyl |
| Daiichi Sankyo INC. | $43.71 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $43.13 | 2025 | Tecvayli, Talvey, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $40.83 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $39.64 | 2019 | |
| Pfizer INC. | $36.18 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.66 | 2019 | |
| Lilly USA, LLC | $25.44 | 2019 | |
| Eisai INC. | $17.59 | 2019 | |
| Exelixis INC. | $16.44 | 2019 | |
| Emd Serono, INC. | $16.33 | 2019 | |
| Genzyme Corporation | $16.15 | 2019 | |
| Mylan Institutional INC. | $14.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2019 | |
| Clovis Oncology, INC. | $13.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.37 | 2019 | |
| Array Biopharma INC | $12.21 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.21 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.12 | 2019 | |
| Dova Pharmaceuticals | $11.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.06 | 2019 | |
| Gilead Sciences, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveen Ranganath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.